Some 3.1% of Quad patients discontinued treatment due to adverse events, versus 5.1% in the comparison arm. Gilead R&D chief Norbert Bischofberger said that the 90% response rate observed on the Quad arm "is an unprecedented result and speaks to the potency, safety and convenience of an integrase-based single-tablet regimen".